Return to search

Clinical Course of Rattlesnake Bite Victims Treated without Antivenom

A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine. / The standard treatment for rattlesnake envenomation (RSE) is antivenom.
The clinical course of patients treated with antivenom is well described.
Prior to 2000, only a whole IgG AV (IgGAV) associated with high rates of
hypersensitivity reactions (HSS) was available to treat RSE. Since 2000,
Crotalidae Polyvalent Immune Fab (FabAV), which has a better safety profile
than IgGAV, has been primarily used.
Patients with RSE may not be treated with AV for a variety of reasons
including history or perceived risk of HSS, patient refusal, drug shortage, or
clinical impression that AV is not indicated.
Research Question: What outcomes are associated with moderate to severe
RSEs treated without antivenom?

Identiferoai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/627152
Date28 March 2018
CreatorsChang, Phoebe
ContributorsThe University of Arizona College of Medicine - Phoenix, Curry, Steven MD
PublisherThe University of Arizona.
Source SetsUniversity of Arizona
Languageen_US
Detected LanguageEnglish
TypeThesis
RightsCopyright © is held by the author. Digital access to this material is made possible by the College of Medicine - Phoenix, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.

Page generated in 0.0021 seconds